A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: melanoma | head and neck cancer | bladder cancer | myeloma | gastric cancer | non-small cell lung cancer | Solid and Hematological Malignancies | lung cancer
Age: Between 18 - 100 Years
Gender: Male or Female
Histologically or cytologically confirmed diagnosis of advanced solid or hematologic malignancy or recurrent disease, as described in the respective Adaptimmune clinical treatment protocol (including, but not limited to myeloma, melanoma, NSCLC, head and neck, gastric and bladder cancer)
Ability to provide a blood sample
Ability to provide a tumor tissue sample
Any bleeding diathesis or coagulopathy, which at the discretion of the Investigator may put the subject at risk
Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the screening study procedures
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required